GoHealth’s Post

When it comes to securing investment, understanding why some investors pass on opportunities is key to refining your approach. Investment mandates, risk tolerance, and differing views on success play significant roles in these decisions. Gaining insight into these factors can help Medtech companies better align their strategies with investor expectations. In our latest LSI Europe '24 panel, "Investors That Pass: An Open Dialogue on Investment Mandates and Definitions of Success," we’ll engage with investors who will openly discuss the factors that lead them to pass on certain opportunities. This panel will provide an inside look at how different investors define success and what truly drives their investment decisions. We’ll hear perspectives from: • Alexei Mlodinow (Moderator) — SIA (Acquired by Integra LifeSciences)) • Diana Saraceni — Panakes Partners • Dr. Irit Yaniv — Almeda Ventures Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

CG’s Boston Growth Conference begins on August 13. This event brings together investors from across the globe with some of the best and most promising growth companies in our core sectors - Technology, Healthcare and Sustainability. Now in its 44th year, the CG Boston Conference has become one of the industry's premier investment conferences for companies and investors focused on growth. CG Australia is strongly represented at this event – and are taking over 14 ASX-listed companies to have 1x1 meetings with US/global investors. A huge thanks to the ASX CEOs and founders joining us – Bob Cruickshank and Will Lopes from Catapult; Clive Cuthell and Andreas Schwer from Electro Optic Systems; Mark Heine, David Kenneson and Margaret Warrington from EROAD; Gary Miles from Gentrack Ltd (Global); Chris Basta, Deanne Miller and Marc Voigt from Immutep Limited; Dominic Allen, Taso Arima and Toby E. Symonds from IperionX; Nick Carnell, Adrian Gleeson and Ali Kronebusch from Johns Lyng Group; Ancila Desai and Rick Ratliff from MedAdvisor Solutions AU; Jon Pilcher from Neuren Pharmaceuticals Limited; Josh Goines and Skander Malcolm from OFX; Swami Raote from PolyNovo Limited; Rohan Hockings and Sri Mudumba from PYC Therapeutics (ASX: PYC); Tim Levy from Qoria; and Michael Goldsworthy from Silex Systems Limited. The numbers are looking strong again this year – with over 10,000 1x1 meeting requests from 559 institutions and 668 VC/PEs for the 466 companies. We’re looking forward to three days of insightful conversations as industry leaders, analysts and strategists discuss emerging trends, actionable ideas, and future growth themes

Quote: "...if you really want to invest in #healthcarerealestate, you cannot only focus on your immediate tenant. Success comes from the outcome of the patient.” Didier Choukroun, President & CEO, SPHERE Investments. #medicalrealestate #medicaloffice #medicalofficeinvestors #revista

On May 8th 2024, Trevor Polischuk, Ph.D., M.B.A. presented at the annual Frostrow Capital LLP Investment Seminar. He spoke about upcoming innovations in Oncology, Alzheimer's and Obesity spaces, catalysts in 2024 and beyond, and how the US presidential elections will effect the healthcare sector. You can watch the full presentation here 👉 https://lnkd.in/ehbz-UCX April factsheet: https://lnkd.in/eXVW2NUU Find out more here: https://lnkd.in/eRNN7UZ6 Investments involve risks. The value of investments and income derived from them may go down as well as up and you may not receive back all the money which you invest. Past performance is no guarantee of future performance.

Learn how Malgorzata Kluba's diverse background in science has enriched her problem-solving toolkit, offering a multidimensional view crucial in analyzing biotech companies and healthcare investments. “My scientific background provides a unique perspective, robust analytical framework, and commitment to evidence-based choices crucial in biotech and healthcare investments.” Whatever your story, your path can lead to Candriam . Would you like to join us? 👉 https://lnkd.in/efbCNMT4 #candriam #investing4tomorrow

🌟 Exciting Opportunity Alert! 🌟 Join Stewart Heath, CPA, and me on July 11, 2024, at 12 PM EST for a Live Investment Webinar. We're diving deep into the potential of medical space investments with our 500 Cahaba Partners project. Take advantage of key insights that could shape your investment future! 🏥💼 👉 Register now and unlock the potential to grow your portfolio. This is an exclusive opportunity you don't want to miss. Check out the link in the comments for more details and to secure your spot. See you there! #InvestmentOpportunity #Webinar #MedicalRealEstate

💡 New Investor Call: Building the next big thing in health tech? Innovestor Life Science, a 90m€ Finland-based fund, is actively seeking new investment opportunities in the Nordics and Baltics! If you're developing science-based or evidence-backed digital health and therapeutics products, this Investor Call could be the perfect fit for you. Details: - Investment Stage: Pre-Seed to Series A - Investment Range: 500k€-3m€ - Focus: All therapeutic areas - Region: Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania To learn more and apply on R2GConnect: https://lnkd.in/dAjbQ2Kc #Investors: Visit R2GConnect.com to set up your own 'Investor Call' for #free. For a demo, contact Sorin STIRCU, Partnerships Manager: https://bit.ly/3TGL2kF #StartupFunding #VentureCapital #HealthTech #EarlyStageInvesting #InvestmentOpportunities

Thematic ETFs are one way to enter the healthcare investing space, with opportunities for further niche investing in #healthtech as well. To learn more about how the team at Langar has created our healthtech ETF, its current holdings, & daily trading data, visit langarfunds.com. #healthcare #innovation #investing #ETF #thematicETF

💡 New Investor Call: Building the next big thing in health tech? Innovestor Life Science, a 90m€ Finland-based fund, is actively seeking new investment opportunities in the Nordics and Baltics! If you're developing science-based or evidence-backed digital health and therapeutics products, this #InvestorCall could be the perfect fit for you. Details: - Investment Stage: Pre-Seed to Series A - Investment Range: 500k€-3m€ - Focus: All therapeutic areas - Region: Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania To learn more and apply on R2GConnect: https://lnkd.in/dAjbQ2Kc #Investors: Visit R2GConnect.com to set up your own 'Investor Call' for hashtag#free. For a demo, contact Sorin STIRCU, Partnerships Manager: https://bit.ly/3TGL2kF   #StartupFunding #VentureCapital #InvestorCall #HealthTechInvesting #EarlyStageInvesting #InvestmentOpportunities #DealFlow

You may want to add this panel to your schedule during LSI Europe ‘24! Investors That Pass: An Open Dialogue on Investment Mandates and Definitions of Success Alexei Mlodinow (Moderator) — SIA (Acquired by Integra LifeSciences) Diana Saraceni — Panakes Partners Dr. Irit Yaniv — Almeda Ventures When it comes to securing investment, understanding why some investors pass on opportunities is key to refining your approach. Investment mandates, risk tolerance, and differing views on success play significant roles in these decisions. Gaining insight into these factors will help you align your strategy with investor expectations (which is key). During this panel, investors will openly discuss the factors that lead them to pass on certain opportunities. This panel will show how different investors define success and what truly drives their investment decisions. Join us Sept 16th-20th to hear more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today before we reach capacity!